Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines With AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Two Monovalent and One Bivalent)

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 12 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SP 0253 (Primary) ; AS03A
Indications COVID 2019 infections
Focus Adverse reactions; Pharmacodynamics; Registrational
Acronyms VAT00002
Sponsors Sanofi Pasteur

Most Recent Events

07 May 2024 Status changed from active, no longer recruiting to completed.
03 Jan 2023 Planned End Date changed from 19 Jul 2023 to 16 Jul 2024.
03 Jan 2023 Planned primary completion date changed from 19 Jul 2023 to 16 Jul 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight